Tags Posts tagged with "marijuana stock"

marijuana stock

2 1402
Marijuana Stocks Cannabis Stocks
 

mCig Inc. (MCIG) Broadens Construction Project Portfolio and Expands Cannabis Supply Division

 

mCig Inc. ( OTCQB : MCIG ), a diversified company servicing the legal cannabis, hemp and CBD markets, is pleased to announce the latest project updates for Grow Contractors (its construction and consulting division), in addition to the latest expansion of its cannabis supply division into the California cannabis market with record sales driven by recent recreational legalization in Nevada.

 

 


Click Here Now To Read (MCIG) Release


Marijuana Stocks on the Rise; What About Consumer Happiness?

 

Stocks in the medical marijuana industry have been hitting new highs for almost a year at this point, and the reasons behind it are quite obvious.

 



Click Here Now To Read Full Article


 

 

Nevada Marijuana Industry Spurs Growth For mCig (MCIG)

The opening of Nevada’s recreational marijuana market has been a catalyst to many companies, however, some have benefited more than others.

Some of the biggest beneficiaries have been the vertically integrated companies as well as the holding companies.

One company that has benefited the most is mCig Inc. (MCIG). The company is levered to several legal cannabis markets and it has benefited from its unique and significant exposure to the Nevada market.

 


Click Here Now To Read Full Article


0 1309
marijuana_glaucoma
 

PotNetwork Holding, Inc. (POTN) Executes Diversification Strategy to Expand Position into the Cannabis Sector

PotNetwork Holding, Inc. ( OTC : POTN ), (“Company”) is very pleased to announce the reacquisition of PotNetwork.com, an online resource originally designed to become a leading industry specific news and content provider for the cannabis marketplace.


Click Here Now To Read (POTN) Release


Marijuana Stocks The Good The Bad The Ugly For Biotech

Although the biotech industry is poised to be one of the greatest beneficiaries of the legal cannabis movement, investors must be cautious with many of the companies focused on this opportunity. While opportunity is vast, it is also expensive and many of these companies do not have the capital needed to execute on its strategy. We have highlighted three biotech cannabis firms below in order of favorability and will continue to monitor how they execute on their plan from here.


Click Here Now To Read Full Article


 

 

Will These Marijuana Stocks Be The Future Of The Industry

Unless you’ve been hiding under a rock somewhere, you’re probably aware that the marijuana industry is booming. With more than half the U.S. legalizing medical marijuana, several legalizing recreational marijuana, and Canada recently making recreational marijuana legal nationwide, demand is greater than ever. Promising marijuana-based drugs could be on the market in the near future.


Click Here Now To Read Full Article


0 1326
Marijuana-Stocks-Cannabis-nug-18
 

PotNetwork Holding, Inc. (POTN) Restocks Popular CBD Chill Gummies Inventory

 

PotNetwork Holding, Inc. (OTC Pink: POTN) is pleased to announce that Diamond CBD’s Chill Gummy line has been restocked and is once again available for sale. “We are happy to announce that our popular Gummy Bears and other gummy edibles once again grace our shelves. As a result of an overwhelming influx of inquiries, we have opted to publicly announce that our gummies are stocked, available and ready to be shipped,” stated Maria Gomez, Regional Vice President of Sales, Diamond CBD.

 

 


Click Here Now To Read (POTN) Release


Why Should You Invest in Marijuana Stocks ?

When it comes to investing in marijuana (specifically medical marijuana) there are many reasons why it’s a smart move. Because of the new nature of the market, the potential for gain remains incredibly high as predictions for future charts project upwards of $5 billion in growth in the next decade. The time to get in is now.


Click Here Now To Read Full Article


 

 

One CBD Company That Could Be Outpacing Industry Leaders

Among the many segments of the marijuana industry that marijuana stock traders pay attention to, CBD or cannabidiol has taken on a major role. This is not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market is projected t to see, CBD companies are in the spotlight


Click Here Now To Read Full Article


 

0 1053
marijuana stocks
 

Marijuana Stocks Could Fly If This Measure Gets Passed

 

U.S. Attorney General Jeff Sessions is reportedly trying to build support to go after companies that sell marijuana in states that have legalized the drug. However, while the executive branch contemplates fighting marijuana, the legislative branch is taking the opposite approach.

 

 


Click Here Now To Read Full Article


 

What To Know When Investing In Marijuana Stocks

 

 

Legal Marijuana is the fastest growing industry in the United States. In 2016, cannabis sales in North America went up 30% from 2015 to reach $6.7 billion.

And looking into the future with more states, Canada and countries around the world making their way toward legalization this already extraordinary speed of growth is actually set to pick up. Canada’s recent decision to legalize recreational cannabis by next summer is expected to create a $23 billion industry that could be bigger than beer and wine.

 

 


Click Here Now To Read Full Article


 

 

 

Working In The Marijuana Industry Is Tougher Than You Think

Those who work in the marijuana industry with in the United States were to ever come together, there would be more of you than there are massage therapists, bakers or other classic paths to the middle class.

 


Click Here Now To Read Full Article


 

0 3666
Marijuana-stocks-biotech

Marijuana stocks continue to trade volatile and Tetra Bio Pharma (TBP.CN) (TBPMF) has been one of the top performers recently. The shares rallied 22% last week and Tetra is well positioned to move significantly higher.

We recently highlighted Tetra Bio and want to provide an update on the company after last week’s move higher.

Continues to Strengthen Management Team

One of the major focuses of Tetra this year has been on its management team and earlier this month, the company added Dr. Bill Cheliak to its Board of Directors.

Dr. Cheliak is CEO of Panag Pharma, a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. He has over 20 years of experience as an entrepreneur and brings extensive deal making experience to the company. Dr. Cheliak currently serves as a Director for Solarvest and is Vice Chair of the Government of Canada’s Networks Centers Excellence Standing Selection Committee and Chair of the NCE Monitoring Committee.

Earlier in May, Tetra Bio further strengthened its management team after it announced that Robert Bechard was appointed to the position of Vice President, Finance and Business Development.

A Focus on Cannabis Biotech Treatments

The addition of Dr. Bill Cheliak to the Board comes one-week after Tetra Bio signed a definitive agreement with Panag Pharma for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation.

Per the definitive agreement, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra has a right of first negotiation for future cannabinoid-based products.

Tetra will work in close collaboration with Panag’s team of experts to ensure a rapid and successful development leading to marketing authorization. Panag will continue work in the development of novel products for unmet medical need and Tetra will take the lead in commercializing these novel drug products.

Positioned to Execute

The signing of a definitive agreement follows the submission of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease

Tetra is focused on developing cannabinoid based pharmaceutical treatments for indications that are multi-billion-dollar opportunities and we think these steps have significantly improved the company’s position within the biotech sector. This is a stock to watch and one we suggest putting toward the top of your radar screens.


 

Disclaimer: Pursuant to an agreement between MAPH and Tetra Bio-Pharma, we were hired for a period of 90 days to publicly disseminate information about (TBPMF) including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for and were paid 250,000 restricted common shares of Tetra Bio-Pharma. We may buy or sell additional shares of (TBPMF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 1090
Marijuana-stocks-scientific-advisory-omhe

Omni Health, Inc. Expands Scientific Advisory Board, Adds Dr. Lawrence E. Samuels

MIAMI, FL–(Marketwired – Jun 1, 2017) – Omni Health, Inc. ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, announced that Lawrence E. Samuels, MD, has joined its Scientific Advisory Board (SAB). The SAB will work closely with the OMHE management team to advance the Company’s product development programs. “We’re honored that Dr. Samuels, a renowned inventor & scientist has chosen to serve on our Scientific Advisory board,” said Andrey Soloviev, OMHE’s Chief Executive Officer. “His ongoing technical expertise and innovative guidance will allow us to move strategically with our resources and accelerate development of our early-stage pipeline products to run parallel to our existing business.”

Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke’s Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors’ offices and medical facilities.

Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He’s a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.

The global wellness products industry is currently a $569 billion industry, and anti-aging is one of the fastest growing categories. The market research firm Global Industry Analysts estimates that a boomer fueled consumer base “seeking to keep the dreaded signs of aging at bay” will push US market for anti-aging products from about $80 billion now to more than $114 billion by 2020. Anti-aging skincare is one of the industry’s booming sectors.

CEO Andrey Soloviev further noted, “Our plan for growth accelerates with the synergy created by our scientific board, our current/future product lines and our existing pharmacy which has been operating for 41 years. With Dr. Samuels’ expertise, we expect to innovate, develop multiple lines of products beginning with our flagship skincare line.”

For more information about Omni Health, go to www.OmniHealth.md

About Omni Health Inc.
Omni Health, Inc. ( OTC PINK : OMHE ) is a 41 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

marijuana-stocks-canadian-canada

Canadian cannabis stocks continue to attract new investors, new institutional capital, and new strategic partners as legal recreational cannabis will help the industry see incremental growth for years to come.

Although this week is a short week due to the Monday’s holiday, Canadian firms continue to report significant company developments and we want to highlight three stories that investors need to be aware of. 

Tetra Enters Strategic Partnership and Changes its U.S. Symbol

Tetra Bio-Pharma (TBP.CN: CSE) (TBPMF) signed a definitive agreement with Panag Pharma for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. This partnership combined with the company’s patent filing last week could make this a profitable relationship. Tetra is focused on generating revenue in 2017 by launching retail products via its partnership with Panag.

Under the agreement, Tetra will have the exclusive right to sell the ocular and topical drug products in North America with right of first negotiation for international markets. Tetra will also have a right of first negotiation for future cannabinoid-based products.

Tetra will work with Panag’s team to ensure a rapid and successful process leading to marketing authorization. Panag will continue to develop new novel products for unmet medical need and Tetra will focus on commercializing these products.

Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The company also developed a cannabinoid topical drug product for the local treatment of pain and inflammation.

Tetra also issued a corporate update and highlighted the following:

  • Changed its U.S. OTCQB symbol to TBPMF
  • Issued 501,800 new shares as part as of a service agreement from June 20, 2016.
  • Issued 250,000 new shares as part of a service agreement with MAPH Enterprises to broaden U.S. investor awareness.

 Canadian Biotech Firm to Raise $5+ Million

InMed Pharmaceuticals (IN.CN: CSE) (IMLFF) entered an underwriting agreement with a syndicate of underwriters led by Canaccord Genuity and includes Eight Capital along with Roth Capital Partners (placement agent). The underwriters agreed to purchase, on an underwritten basis, 11,120,000 units at $0.45 each for $5 million in aggregate gross proceeds.

InMed plans to use the proceeds for the following reasons: 1) To support the continued research and development of INM-750 for the treatment of Epidermolysis Bullosa, 2) To further develop the company’s other research and development programs including its biosynthesis assets, 3) For general and administrative expenses, and 4) To fund working capital.

Each unit is comprised of one common share and one-half share purchase warrant. The warrant has an exercise price of $0.65 and will be exercisable for a period of 24 months following the closing date. The offering is expected to close by May 30th. InMed granted the underwriters the option to purchase up to 1,668,000 additional units at $0.45 each for a period of up to 30 days after the closing date. If this option is exercised in full, the company will generate $5.75 million in aggregate gross proceeds.

Marapharm Looks to Enter Nevada’s Recreational Market

Yesterday, Marapharm Ventures (MDM: CSE) (MRPHF) took a significant step forward in its plans to take advantage of the Nevada recreational cannabis market. Marapharm acquired two fully equipped buildings that meet Nevada’s state licensing requirements and the company must move quick if they want to take advantage of this huge opportunity.

Marapharm’s buildings were inspected and given pre-approval for cultivation and processing. If the company can be approved before May 31st and conduct a taxable transaction, it will be allowed to apply for licensing under the state’s recreational program.

Nevada’s department of taxation is currently accepting applications for recreational cultivation, production, lab and retail store licenses, from existing Nevada marijuana establishments that hold valid registration certificates.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in Washington state and Nevada. About three years ago, Marapharm applied in Canada to Health Canada and the application is currently in the in-depth screening process. In September, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

We are on the sidelines but think this is a story and a stock investors should keep an eye on!

 

Author: Michael Berger

 


 

Disclaimer: Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.We may buy or sell additional shares of (IMLFF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Pursuant to an agreement between MAPH and Tetra Bio-Pharma, we were hired for a period of 90 days to publicly disseminate information about (TBPMF) including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for and were paid 250,000 restricted common shares of Tetra Bio-Pharma. We may buy or sell additional shares of (TBPMF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

marijuana stocks

A Revolutionary Cannabis Investment?

Some of the greatest investment minds in the world say, “You invest in management.” And since the birth of MarijuanaStocks.com, few management personnel have shined brighter than Cannabis Wheaton Income Corp. CEO Chuck Rifici. Mr. Rifici has accomplished with Cannabis Wheaton something that no other cannabis industry CEO has. The business model he has implemented is something that we feel every marijuana investor MUST know about. Cannabis Wheaton (KWFLF)(CBW.V) provides a very unique opportunity for marijuana investors by greatly reducing risk while still maintaining tremendous upside potential.

But before we explain the Cannabis Wheaton business model and why we feel EVERY investor should know about it, let’s first take a look at Chuck Rifici. Because as we said earlier, “you invest in management.” And there may not be a more recognizable managerial figure who has done more for the marijuana industry than Mr. Rifici.

Invest in Management

Chuck Rifici is responsible for co-founding and taking public the largest full-scale producer of government-sanctioned marijuana as its CEO in April 2014; a company by the name of Tweed Inc. whose name later changed to Canopy Growth Corp. (TWMJF)(WEED.TO). To this day, Canopy Growth remains the largest public cannabis company with a staggering market cap of approximately $1Billion. In 2016, WEED hit $17.86 approximately 550% higher than the IPO price. It is widely agreed to be the most successful marijuana company to go public and is seen as the benchmark and leader of the industry.

Take a look at how WEED stock has performed over the last 2 years:

marijuana stocks

When considering an investment in any company, it’s important to look at the management team. Who is leading the ship? Is this their first rodeo? Or have they already proven successful in bringing a company to market that has built shareholder value? Well, Chuck Rifici’s track record with co-founding Tweed speaks for itself and gives Cannabis Wheaton shareholders confidence that they have a marijuana industry trailblazer leading their ship.

But Rifici’s resume is filled with much more than just Tweed. In 2011, Rifici was appointed CFO of the Liberal Party of Canada by interim party leader Bob Rae. In 2014, Rifici was also named to the Top Forty under 40 by Ottawa Business Journal, named Alumnus of the Year by the University of Ottawa Faculty of Engineering, and received the Exceptional New Business Award by the Ottawa Chamber of Commerce.

Rifici also sat on the Board of marijuana starlets Supreme Pharmaceuticals (SPRWF) (SL.CN), Aurora Cannabis (ACBFF) (ACB.V), and CannaRoyalty (CNNRF) (CRZ.V). These board positions helped Rifici keep his ear to the ground, expand his network, and gain insight to the marijuana industry in both Canada and the U.S. He actually just resigned from his Supreme Pharma and Aurora Cannabis Board seats because of a slight conflict of interest but mostly to focus all of his time and energy towards building Cannabis Wheaton into a revolutionary cannabis company.

Cannabis Wheaton’s Streaming Model—Revolutionizing Cannabis Investment

Cannabis Wheaton is the first company to bring a streaming business model to the marijuana industry. This unique model can greatly reduce risk for investors while maintaining tremendous upside potential from a booming industry. Streaming business models are normally found in the mining industry and refer to when a company strikes a deal with a miner to purchase all or part of its future metal production in exchange for upfront cash. Perhaps the most notable example is silver giant Silver Wheaton (NYSE: SLW). This works well because mining is a very cash intensive business and requires a lot of upfront capital. And the cannabis industry is about to undergo a massive expansion that will be an serious capital burden on current marijuana producers.

Rifici has said that the marijuana industry must increase total production by 10 times the current rate in order to keep pace with the increased demand for marijuana once the drug is legalized for recreational use. Producers are barely keeping up with cannabis demand from just medical marijuana users, never mind when legal recreational use goes into effect.

Currently, there is only 1.4 million square feet of licensed medical marijuana production facilities in Canada. According to Rifici, 14 million square feet is needed to satisfy the upcoming demand. Such a massive expansion is a major financial burden and carries great risk for companies trying to expand so much so quickly. And that is where the opportunity lies for Cannabis Wheaton.

“We’re going to see tremendous growth in the industry…There have been a lot of announced expansions that fill maybe a third of that gap. But there’s still 6 or 7 million square feet that needs to be built out,” said the Rifici.

Under the streaming model, Cannabis Wheaton will provide marijuana producers with the necessary capital to expand their operations in exchange for a minority equity stake in the company and a portion of their future production at an agreed upon discounted price. The company will also provide their partners with guidance and expertise on facility construction, cultivation, and the licensing process. Rifici has brought to Wheaton several of the early key members of Tweed including the top cannabis legal team in Canada that has helped half a dozen Licensed Producers (LPs) obtain their licenses.

Cannabis Wheaton has already signed 16 streaming deals with 14 partners across 6 different provinces of Canada. Their partners’ credentials include:

  • 2 sales licenses.
  • 3 cultivation licenses.
  • 4 affirmation letters.
  • 5 advanced pre-affirmation stage applicants.

Through these agreements, Cannabis Wheaton already has access to 1.3 million square feet of cultivation by 2019, 30,000 registered medical marijuana patients, and nearly 40 medical cannabis clinics.

One agreement we feel worth mentioning specifically is the company’s deal with Broken Coast Cannabis Ltd., a British Columbia based medical cannabis producer that has established itself as a top provider of high grade cannabis products. Broken Coast’s clean tech production methods and systems deliver consistent premium cannabis. The company was also recently awarded one of the few 18-month Access to Cannabis for Medical Purposes Regulation (ACMPR) licenses, which is a testament to its compliance record.

Broken Coast and its entities will utilize the experience and capital of Cannabis Wheaton to accelerate expansion and scale production in a short period of time. Under the terms of the agreement between the companies, Broken Coast will source a proposed site to complement their current site. The parties expect the new location to accommodate at least 100,000 square foot state-of-the-art cannabis cultivation facility.

Broken Coast will operate the new facility in accordance with its industry best practices and the two companies will share the proceeds with Cannabis Wheaton receiving 49% of the product output.

5 Reasons to Consider Cannabis Wheaton

  1. Licensed Producer Diversification- Because the company is working with such a wide range of cannabis cultivation companies and receiving both an equity stake in those companies and a percentage of the end product, shareholder risk is spread out amongst several companies rather than just one.
  2. Exposure to Tremendous Upside- Usually, reducing risk results in reduced potential reward, too. But not in this case. Even with the reduced risk, shareholders are exposed to the explosive industry expansion that Rifici explained as being a 10x expansion. Current cannabis revenue numbers in Canada will pale in comparison to what we see once legal recreational use goes in effect. Cannabis Wheaton will hold an equity stake in many producers as well as owning portions of the end product at a discounted price.
  3. Geographic Diversification- Cannabis Wheaton has signed agreements with partners across 6 different provinces in Canada. This brings exposure to several different markets and acts almost as a loophole for the company to take advantage of a few question marks the industry has regarding distribution.
  4. Proven Business Model- The streaming business model has already been proven successful for some of the largest metal miners in the world. Silver Wheaton, a streaming company with a market cap of approximately $10Billion, went to this model because they generally have a bullish outlook on the price of silver. So, it makes sense for them to fund a miner’s drilling operations and expansion to purchase the future metal output at a steep discount. Similarly, Rifici and Cannabis Wheaton have a bullish outlook on the production rate and revenue numbers for marijuana in Canada expecting a 10x expansion of the industry. So, it makes sense to help fund the expansion in return for equity ownership and a portion of the end product.
  5. Successful Management- The team behind Cannabis Wheaton has already taken the largest producer of government-sanctioned marijuana public. And it was and remains the most successful IPO in the cannabis space and true leader of the industry. 

Conclusion

Ever since Rifici co-founded Tweed and brought the cannabis juggernaut public in 2014, investors wondered what his next project would be. Rifici said he is proud of what he built with Tweed but was ready to put the past behind him.

“I’m essentially moving on to what I think are far better opportunities in the space,” said the Cannabis Wheaton CEO.

It’s hard to imagine what opportunities could be more successful than a $1Billion market cap, top marijuana producing, cannabis leader that gained 550% from its IPO. But if anyone knows an opportunity in the marijuana space when they see one it’s Chuck Rifici.

Licensed Producers are already having trouble keeping up with demand from about only 130,000 registered medical marijuana patients. When legal recreational use goes into effect, demand is going to skyrocket. The current 1.4 million square feet of cultivation facility space simply isn’t going to cut it. Not even close. The entire industry is racing to undergo a massive expansion that will see cultivation space increase by about 10 times. That type of expansion is extremely costly and carries great risk for individual producers.

However, with their streaming business model, Cannabis Wheaton is de-risking the expansion while still giving investors exposure to the booming industry growth. With 16 agreements already inked with 14 different partners across 6 different provinces, Cannabis Wheaton could very well be revolutionizing the way investors capitalize on the cannabis industry.

 


Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 1622
 

Top 3 Marijuana Stocks Canada Wants To Keep To Themselves

 

Although the Canadian cannabis sector offers tremendous upside, investors need to be cautious and focus on companies that have a differentiated strategy. We have highlighted three Canadian cannabis stocks that trade in both the United States and Canada which we think have long-term upside due to their respective strategy.

 

 


Click Here Now To Read Full Article


 

Local Governments Are Facing Difficulties Trying to Cash In On The Marijuana Industry

 

At the office of Monterey County’s Treasurer-Tax Collector, armed- guards now stand watch over the parking lot and lobby door. A recently restored front office now serves as a secure drop-off point for taxpayers hauling big bags full of cash. A fleet of state-of-the-art currency counters stand ready to quickly record unprecedented sums of paper bills. And the regularly scheduled armored truck pickups are now passing through at a swifter clip.

 

 


Click Here Now To Read Full Article


 

Marijuana Stocks: When We Connect the Dots, You Profit

Over the last couple years, as the marijuana industry has taken flight, it has been our mission to help our readers make money from cannabis. Every once in a while we publish a “Connect the Dots” article highlighting a company or group of companies that we believe have tremendous near-term upside potential. By identifying these companies and providing insight and research otherwise unavailable to the mainstream investor, we have been able to help our readers gain as much as 9,932% in about two and a half years. That is the combined gain percentage that all of our Connect the Dots companies experienced in the weeks and months after we published an article. Let’s take a look at some of our biggest gainers.

 


Click Here Now To Read Full Article


    0 4091
    marijuana stocks

    VBIO has now gained 42% since we re-initiated coverage on the company on April 20th at $1.93. On May 3rd, VBIO rocketed out of the gate hitting a high of $2.74 after announcing the addition of key clinical advisors in gastroenterology. This comes just days after we sent an email to subscribers saying to look for a break above resistance as momentum could pick up soon. And our timing was perfect.

    This is the second time we initiated coverage on this company and the results are beginning to look a lot like the first time. Our initial coverage began back on December 6, 2016, at $1.01. Within less than 1 month, VBIO exploded 320%. Now, here we are less than two weeks into our second round of coverage and VBIO has already gained 42%.

    cannabis stock

    Check out the experience of the advisors the company just added:

    Vitality Biopharma Adds Key Clinical Advisors in Gastroenterology

    Vitality Biopharma announced Dr. Douglas A. Drossman and Dr. Mark Gerich as clinical advisors with expertise in gastroenterology and treatment of digestive disorders.

    Douglas A. Drossman, M.D., is a founder and now President of the Rome Foundation, an independent nonprofit research organization dedicated to improving the lives of people with functional GI disorders. Dr. Drossman is an Emeritus Professor of Medicine and Psychiatry at the University of North Carolina (UNC) School of Medicine. He is a recognized expert in the diagnosis and treatment of narcotic bowel syndrome, a severe form of opiate-induced abdominal pain, having authored seminal publications describing this condition. Dr. Drossman established a program of research in functional GI disorders at UNC more than 25 years ago and has published more than 500 books, scientific articles, and abstracts. He received his MD from Albert Einstein College of Medicine in 1970 and completed medical residencies at the University of North Carolina School of Medicine and the New York University-Bellevue Medical Center.

    Mark Gerich, M.D., currently serves as the Clinical Director of the University of Colorado Crohn’s & Colitis Center and conducts clinical and translational research focused on the pathogenesis and treatment of inflammatory bowel disease (IBD). He received his undergraduate degree from Cornell University and a dual MD/MBA degree from McGill University in Montreal, Quebec, Canada. Dr. Gerich received his internal medicine training at the University of California Davis Medical Center and completed his fellowship in gastroenterology and hepatology at the University of Colorado in 2011. After completing an advanced IBD fellowship at Cedars-Sinai Medical Center in Los Angeles, Dr. Gerich joined the faculty in the Division of Gastroenterology and Hepatology at the University of Colorado.

    These key additions add to an already attractive story unfolding with Vitality Biopharma. And we were some of the first ones to identify the opportunity. Our timing continues to be spot on so stay tuned for further updates regarding VBIO.

     


     

    Disclaimer: Pursuant to an agreement between MAPH and a non affiliate third party, we were previously hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements